STOCK TITAN

[Form 4] NeueHealth, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Jeffrey R. Immelt, a director of NeueHealth, Inc. (NEUE), reported a transaction dated 10/02/2025 showing the disposition of 23,918 shares of common stock, leaving him with 0 shares of direct ownership. The Form 4 explains that on 10/02/2025 the issuer was acquired by NH Holdings 2025, Inc. under a merger agreement and became a wholly-owned subsidiary of the acquirer. Under a Rollover Agreement dated 09/23/2025, the reporting person contributed his issuer common stock and Series A and Series B preferred shares in exchange for ownership units in NH Holdings 2025 SPV, L.P., effective at the merger closing. The filing was signed by an attorney-in-fact on 10/06/2025.

Jeffrey R. Immelt, un direttore di NeueHealth, Inc. (NEUE), ha riportato una transazione datata 10/02/2025 che mostra la cessione di 23.918 azioni ordinarie, lasciandolo con 0 azioni di proprietà diretta. Il modulo 4 spiega che il 10/02/2025 l’emittente è stato acquisito da NH Holdings 2025, Inc. secondo un accordo di fusione ed è diventato una filiale interamente controllata dall’acquirente. Sotto un Rollover Agreement datato 09/23/2025, la persona che presenta la segnalazione ha contribuito le sue azioni ordinarie della società emittente e azioni privilegiate di Serie A e B in cambio di unità di proprietà in NH Holdings 2025 SPV, L.P., efficaci al closing della fusione. Il deposito è stato firmato da un procuratore in giudizio il 10/06/2025.

Jeffrey R. Immelt, director de NeueHealth, Inc. (NEUE), informó una transacción con fecha 10/02/2025 que muestra la disposición de 23,918 acciones ordinarias, dejándolo con 0 acciones de propiedad directa. El Formulario 4 explica que el 10/02/2025 el emisor fue adquirido por NH Holdings 2025, Inc. bajo un acuerdo de fusión y se convirtió en una subsidiaria de propiedad total del adquirente. Bajo un Rollover Agreement con fecha 09/23/2025, la persona informante aportó sus acciones ordinarias del emisor y acciones preferentes de Serie A y B a cambio de unidades de propiedad en NH Holdings 2025 SPV, L.P., con efecto a la clausura de la fusión. El escrito fue firmado por un apoderado el 10/06/2025.

Jeffrey R. Immelt, NeueHealth, Inc. (NEUE)의 이사, 10/02/2025로 날짜가 된 거래를 보고했으며, 보통주 23,918주를 처분하여 직접 소유 주식이 0주가 되었다고 밝힙니다. Form 4는 10/02/2025에 발행회사가 NH Holdings 2025, Inc.에 의해 합병 계약에 따라 인수되었고 매수자의 전액출자 자회사가 되었음을 설명합니다. 09/23/2025에 체결된 Rollover Agreement에 따라 보고자가 발행사 보통주와 시리즈 A 및 시리즈 B 우선주를 NH Holdings 2025 SPV, L.P.의 소유권 유닛으로 교환하여 합병 종결 시에 효력이 발생했습니다. 이 서류는 10/06/2025에 대리인에 의해 서명되었습니다.

Jeffrey R. Immelt, administrateur de NeueHealth, Inc. (NEUE), a déclaré une transaction datée du 10/02/2025 montrant la cession de 23 918 actions ordinaires, le laissant avec 0 actions de propriété directe. Le Form 4 explique que le 10/02/2025 l’émetteur a été acquis par NH Holdings 2025, Inc. dans le cadre d’un accord de fusion et est devenu une filiale en propriété exclusive de l’acquirant. En vertu d’un Rollover Agreement daté du 09/23/2025, la personne faisant la déclaration a apporté ses actions ordinaires de lémetteur et des actions préférées des séries A et B en échange d’unités de propriété dans NH Holdings 2025 SPV, L.P., effectives à la clôture de la fusion. Le dépôt a été signé par un mandataire le 10/06/2025.

Jeffrey R. Immelt, ein Direktor von NeueHealth, Inc. (NEUE), berichtete eine Transaktion datiert auf 10/02/2025, die die Veräußerung von 23.918 Stammaktien zeigt, wodurch er 0 Anteile direkter Eigentümerschaft behält. Das Formular 4 erklärt, dass am 10/02/2025 der Emittent gemäß einer Fusionsvereinbarung von NH Holdings 2025, Inc. übernommen wurde und eine hundertprozentige Tochtergesellschaft des Erwerbers wurde. Unter einer am 09/23/2025 datierten Rollover Agreement hat der meldende Person seine Emittenten-Stammaktien und Vorzugsaktien der Serien A und B im Austausch gegen Eigentumsanteile an NH Holdings 2025 SPV, L.P. eingebracht, wirksam zum Abschluss der Fusion. Die Einreichung wurde von einem Bevollmächtigten am 10/06/2025 unterschrieben.

Jeffrey R. Immelt, مدير في NeueHealth, Inc. (NEUE), أبلغ عن صفقة بتاريخ 10/02/2025 تُظهر التصرف في 23,918 سهماً عاديّاً، تاركاً له 0 أسهم ملكية مباشرة. تشرح النماذة Form 4 أنه في 10/02/2025 تم استحواذ المُصدر بواسطة NH Holdings 2025, Inc. بموجب اتفاق اندماج وأصبح فرعاً مملوكاً بالكامل للمشتري. بموجب Rollover Agreement بتاريخ 09/23/2025، قام الشخص المبلّغ بتقديم أسهمه العادية للمُصدر وأسهم المدعوّة من السلسلتين A وB مقابل وحدات ملكية في NH Holdings 2025 SPV, L.P., سارية عند إغلاق الاندماج. تم توقيع الملف من وكيل نيابة بتاريخ 10/06/2025.

Jeffrey R. Immelt,是NeueHealth, Inc. (NEUE)的董事,报告的交易日期为10/02/2025,显示处置了23,918股普通股,直接所有权仍为0股。Form 4 解释称,在10/02/2025,发行人被NH Holdings 2025, Inc.依据合并协议收购,成为收购方的全资子公司。根据日期为09/23/2025Rollover Agreement,申报人将其发行人的普通股以及系列A与系列B优先股换成NH Holdings 2025 SPV, L.P.的所有权单位,该安排在合并完成时生效。该申报于10/06/2025由一名代理签署。

Positive
  • Merger completed with issuer becoming a wholly-owned subsidiary of NH Holdings 2025, Inc. on 10/02/2025
  • Rollover preserved economic interest by exchanging common and preferred shares for corresponding units on a one-for-one basis
Negative
  • Reporting person now has 0 shares of direct common stock following the reported disposition
  • Direct public reporting reduced, shifting ownership to an indirect holding vehicle controlled by private funds

Insights

Director moved from direct holdings to rolled-over private fund units after a merger.

The reported sale of 23,918 common shares and resulting 0 direct ownership reflects a common post-acquisition rollover where public stock is exchanged for private vehicle units. This shifts the reporting structure from direct public equity to indirect interest via NH Holdings 2025 SPV, L.P. which is controlled by funds affiliated with New Enterprise Associates, Inc.

This change reduces publicly reportable direct holdings while preserving economic exposure through the rollover units; monitor any future Section 16 filings for disclosures about the number or type of units held and any sale or distribution events within 12 months.

The transaction stems from a closing of a merger and a contemporaneous rollover agreement.

The Form 4 ties the disposition to a Merger Agreement where the issuer merged into a Merger Sub and became a wholly-owned subsidiary of NH Holdings 2025, Inc. The Rollover Agreement converted public common and preferred shares into corresponding units on a one-for-one basis in the acquiring holding structure.

Key items to watch are any disclosures of the holding vehicle's capital structure and timing of liquidity events for rollover units, since those determine when former public holders might realize value; expect such details in follow-on filings or disclosure documents from the acquirer.

Jeffrey R. Immelt, un direttore di NeueHealth, Inc. (NEUE), ha riportato una transazione datata 10/02/2025 che mostra la cessione di 23.918 azioni ordinarie, lasciandolo con 0 azioni di proprietà diretta. Il modulo 4 spiega che il 10/02/2025 l’emittente è stato acquisito da NH Holdings 2025, Inc. secondo un accordo di fusione ed è diventato una filiale interamente controllata dall’acquirente. Sotto un Rollover Agreement datato 09/23/2025, la persona che presenta la segnalazione ha contribuito le sue azioni ordinarie della società emittente e azioni privilegiate di Serie A e B in cambio di unità di proprietà in NH Holdings 2025 SPV, L.P., efficaci al closing della fusione. Il deposito è stato firmato da un procuratore in giudizio il 10/06/2025.

Jeffrey R. Immelt, director de NeueHealth, Inc. (NEUE), informó una transacción con fecha 10/02/2025 que muestra la disposición de 23,918 acciones ordinarias, dejándolo con 0 acciones de propiedad directa. El Formulario 4 explica que el 10/02/2025 el emisor fue adquirido por NH Holdings 2025, Inc. bajo un acuerdo de fusión y se convirtió en una subsidiaria de propiedad total del adquirente. Bajo un Rollover Agreement con fecha 09/23/2025, la persona informante aportó sus acciones ordinarias del emisor y acciones preferentes de Serie A y B a cambio de unidades de propiedad en NH Holdings 2025 SPV, L.P., con efecto a la clausura de la fusión. El escrito fue firmado por un apoderado el 10/06/2025.

Jeffrey R. Immelt, NeueHealth, Inc. (NEUE)의 이사, 10/02/2025로 날짜가 된 거래를 보고했으며, 보통주 23,918주를 처분하여 직접 소유 주식이 0주가 되었다고 밝힙니다. Form 4는 10/02/2025에 발행회사가 NH Holdings 2025, Inc.에 의해 합병 계약에 따라 인수되었고 매수자의 전액출자 자회사가 되었음을 설명합니다. 09/23/2025에 체결된 Rollover Agreement에 따라 보고자가 발행사 보통주와 시리즈 A 및 시리즈 B 우선주를 NH Holdings 2025 SPV, L.P.의 소유권 유닛으로 교환하여 합병 종결 시에 효력이 발생했습니다. 이 서류는 10/06/2025에 대리인에 의해 서명되었습니다.

Jeffrey R. Immelt, administrateur de NeueHealth, Inc. (NEUE), a déclaré une transaction datée du 10/02/2025 montrant la cession de 23 918 actions ordinaires, le laissant avec 0 actions de propriété directe. Le Form 4 explique que le 10/02/2025 l’émetteur a été acquis par NH Holdings 2025, Inc. dans le cadre d’un accord de fusion et est devenu une filiale en propriété exclusive de l’acquirant. En vertu d’un Rollover Agreement daté du 09/23/2025, la personne faisant la déclaration a apporté ses actions ordinaires de lémetteur et des actions préférées des séries A et B en échange d’unités de propriété dans NH Holdings 2025 SPV, L.P., effectives à la clôture de la fusion. Le dépôt a été signé par un mandataire le 10/06/2025.

Jeffrey R. Immelt, ein Direktor von NeueHealth, Inc. (NEUE), berichtete eine Transaktion datiert auf 10/02/2025, die die Veräußerung von 23.918 Stammaktien zeigt, wodurch er 0 Anteile direkter Eigentümerschaft behält. Das Formular 4 erklärt, dass am 10/02/2025 der Emittent gemäß einer Fusionsvereinbarung von NH Holdings 2025, Inc. übernommen wurde und eine hundertprozentige Tochtergesellschaft des Erwerbers wurde. Unter einer am 09/23/2025 datierten Rollover Agreement hat der meldende Person seine Emittenten-Stammaktien und Vorzugsaktien der Serien A und B im Austausch gegen Eigentumsanteile an NH Holdings 2025 SPV, L.P. eingebracht, wirksam zum Abschluss der Fusion. Die Einreichung wurde von einem Bevollmächtigten am 10/06/2025 unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
IMMELT JEFFREY R

(Last) (First) (Middle)
C/O NEUEHEALTH, INC.
9250 NW 36TH ST SUITE 420

(Street)
DORAL FL 33178

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NeueHealth, Inc. [ NEUE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/02/2025 D(1) 23,918 D (2) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc.
2. Pursuant to the Rollover Agreement, dated as of September 23, 2025 (the "Rollover Agreement"), entered into by and among NH Holdings 2025 SPV, L.P. ("Holdings"), NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and the Reporting Person, the Reporting Person contributed its shares of Issuer common stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") to Holdings in exchange for Holdings common units, series A preferred units and series B preferred units on a one for one basis in accordance with the Rollover Agreement, and effective as of the effective time of the Merger (the "Effective Time").
Remarks:
/s/ Eric Halverson for Jeffrey R. Immelt, Attorney-in-Fact 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jeffrey R. Immelt report in the Form 4 for NEUE?

The Form 4 reports the disposition of 23,918 common shares on 10/02/2025, leaving the reporting person with 0 direct shares.

Why were the shares disposed of according to the filing?

The filing states the disposition occurred in connection with a merger where the issuer became a wholly-owned subsidiary of NH Holdings 2025, Inc., and shares were contributed under a Rollover Agreement dated 09/23/2025.

Does the reporting person retain any economic interest after the transaction?

Yes. Under the Rollover Agreement the reporting person received Holdings common units and series preferred units on a one-for-one basis, indicating retained indirect economic exposure.

Who controls the acquiring entities noted in the Form 4?

The filing states Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc..

When was the Form 4 signed and filed?

The signature block shows the form was signed by an attorney-in-fact on 10/06/2025.
NeueHealth Inc

NYSE:NEUE

NEUE Rankings

NEUE Latest News

NEUE Latest SEC Filings

NEUE Stock Data

60.94M
7.28M
9.45%
58.37%
0.14%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
DORAL